Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial
Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease
Objective: To investigate the clinical correlates of gut microbe-derived tyrosine decarboxylase (tdc) and motor dysfunction in Parkinson’s Disease (PD) patients. Background: Gut microbe-derived tdc was…The effect of cathodal transcranial direct current stimulation in the treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease: a preliminary report.
Objective: Our study aims to demonstrate the possible effect of transcranial direct current stimulation (tDCS) in the treatment of Levodopa-induced dyskinesias (LIDs) in patients with…Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy
Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…Delta(0.5-2Hz) Spectral Power reduction in the frontal region in NREM Sleep are Associated with dyskinesia in Parkinson’s Disease
Objective: Our study aimed to establish the objective physiological indicators assessed by polysomnography(PSG) that are associated with dyskinesia in PD patients.Our study aimed to establish…Motor complications in Parkinson’s disease
Objective: To determine the presence, severity, functional impact and predisposing factors of motor complications. Background: Motor complications are well recognized in Parkinson’s disease (PD), but…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…Genetic diagnosis of parkinsonian phenotype of Machado Joseph Diseasep (SCA-3) presenting with dopa induced dyskinesia
Objective: We report a rare type IV parkinsonian phenotype of MJD having a rare genetic mutation. SCA type 3 (SCA3), also known as Machado-Joseph disease…Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 49
- Next Page »